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We identified the epitopes on the preS1 which induce antibodies that neutralize both ad and ay subtypes of hepatitis B virus
(HBV). Previously we generated murine monoclonal antibodies KR359 and KR127 that bind specifically to the preS1 of HBV.
In this study we have performed fine mappings of the epitopes of the antibodies by examining their reactivity with GST fusion
proteins, which contain a series of deletion mutants of the preS1. KR359 and KR127 specifically recognize aa 19–26 and
37–45 of the preS1, respectively. The antibodies neutralized both adr and ayw subtypes of the virus in an in vitro neutralization
assay using in vitro infection of adult human hepatocyte primary culture by HBV. The epitopes showed little sequence
divergence and the antibodies bound to the preS1 of all the HBV subtypes and variants tested. © 2000 Academic PressINTRODUCTION
Human hepatitis B virus (HBV) is a small enveloped
DNA virus which causes acute and chronic hepatitis in
humans (Ganem and Varmus, 1987). The HBV envelope
contains three related surface glycoproteins called the
large (L), middle (M), and small (S) proteins. All these
proteins are the product of a single open reading frame,
which is divided into the preS1, preS2, and S regions
(Heermann et al., 1984). They arise from separate trans-
lation initiations at each of the three inframe AUG codons
and share a common C-terminal S open reading frame.
The S protein (P24) and its glycosylated form (GP27) are
encoded by the S region. The M protein (GP33/GP36)
contains preS2 (55 amino acids [aa]) and S regions, and
the L protein (P39/GP42) contains preS1 (108 or 119 aa,
depending on the antigenic subtype), preS2, and S re-
gions. The S protein carries the common group-specific
determinant a and two sets of mutually exclusive subtype
determinants d/y and w/r and thus the four major sub-
types (adw, adr, ayw, and ayr) of the HBsAg denote the
antigenic types of HBV (Courouce et al., 1982).
In addition to the infectious virus particles, cells in-
fected by HBV produce large quantities of noninfectious
subviral particles of two other morphological forms,
22-nm spherical particles and filaments of 22-nm diam-
eter. The S protein is found in large quantities on all three
particle types, whereas the L protein is preferentially
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irst authors.
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9localized on infectious virus particles (Stibbe and Ger-
lich, 1983; Heermann et al., 1984). Thus, the L protein
was speculated to have a pivotal function in viral infec-
tivity and assembly (Neurath et al., 1986; Persing et al.,
1986; Ou and Rutter, 1987). Also, the aa 21–47 of the
preS1 was proposed to contain a specific binding site for
human hepatocyte receptor (Neurath et al., 1986; Pon-
tisso et al., 1989).
The envelope proteins carry epitopes involved in im-
mune defense mechanisms (Dreesman et al., 1982;
Heermann et al., 1987; Klinkert et al., 1986; Milich, 1987).
During infection, the antibodies are detectable at various
stages of the disease and convalescence: anti-preS an-
tibodies develop early, whereas anti-S antibodies appear
later and signal virus elimination (Klinkert et al., 1986;
Heermann et al., 1987; Milich, 1987; Neurath et al., 1989).
In the case of S protein, the common a determinant was
shown to elicit the protective and neutralizing antibodies
(Bhatnager et al., 1982; Dreesman et al., 1982); moreover,
the monoclonal antibody specific to the common a de-
terminant was demonstrated to have neutralizing activity
(Iwarson et al., 1985; Ogata et al., 1993). On the contrary,
the role of anti-preS antibodies in virus neutralization is
less well studied. In the case of preS1, antiserum to
peptide preS1(aa 21–47) was shown to neutralize HBV
infection in chimpanzee (Neurath et al., 1989). However,
no anti-preS1 monoclonal antibody with virus-neutraliz-
ing activity has been reported. This may be a result of the
lack of reproducible in vitro HBV infection system using
a cell line and experimental animal model except chim-
panzees. Recently, we found that in vitro neutralization
assay using in vitro infection of adult human hepatocyte
culture by HBV is specific and reproducible enough to
evaluate the neutralizing activities of anti-HBsAg mono-
clonal antibodies (Ryu et al., 1997).
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10 MAENG ET AL.In this study, we have mapped the epitopes of the
anti-preS1 monoclonal antibodies KR359 and KR127, and
showed that each of the antibodies neutralizes both the
adr and ayw subtypes of the virus in the in vitro neutral-
zation assay. The neutralizing epitopes (aa 19–26 and
7–45) showed little sequence divergence among HBV
ubtypes and the antibodies bound to the preS1 of all the
BV variants tested.
RESULTS AND DISCUSSION
pitope mapping of anti-preS1 monoclonal antibodies
R127 and KR359
Previously, we generated anti-preS1 monoclonal anti-
odies KR359 (IgG1, k) and KR127 (IgG2a, k) by immu-
izing mice with the preS1 peptide (aa 1–56) conjugated
o keyhole limpet hemocyanin, and confirmed that the
ntibodies bind to native HBV particles, but not to the
reS2 or S protein (Ryu et al., 2000). In addition, the
pitopes of KR359 and KR127 on the preS1 were roughly
FIG. 1. Schematic representation of the GST fusion proteins containin
bold style indicate the epitope of KR359 or KR127 antibody.apped as aa 21–35 and aa 35–47, respectively. In this
tudy, fine mappings of their epitopes were performed.
p
tTo determine the epitope of KR359, a series of amino-
r carboxyl-terminal deletion mutants of the preS1 region
ene were synthesized by polymerase chain reaction
PCR) and fused to the 39 end of the glutathione S-
ransferase (GST) gene to construct a series of expres-
ion plasmids (Fig. 1). Each plasmid was introduced into
scherichia coli, and the protein extracts of the induced
ecombinant cells were analyzed by 12.5% SDS–polyac-
ylamide gel electrophoresis (PAGE). The series of GST-
reS1 fusion proteins were efficiently expressed in E.
oli and could be visualized by Coomassie blue staining
Figs. 2A and 2B). Western blot analysis of the amino-
erminal deletion mutants using KR359 showed that the
reS1(aa 19–56, 19–56) retained the full binding activity
o the antibody, while the preS1(20–56) almost lost the
inding activity (Fig. 2C), indicating that the amino acid at
osition 19 is necessary for the antibody binding. In the
ase of the carboxyl-terminal deletion mutants, the
reS1(1–20) did not bind to the antibody and the
reS1 or the deletion mutants used for epitope mapping. The letters inreS1(1–24) bound weakly, while the preS1(1–26) re-















11NEUTRALIZING EPITOPES ON HEPATITIS B VIRUS PreS1cate that the epitope of KR359 is located at aa 19–26 of
the preS1.
To map the fine epitope of KR127, a series of amino-
or carboxyl-terminal deletion mutants of the preS1(1–
119) were constructed (Fig. 1) and expressed in E. coli
as GST fusion proteins (Fig. 3A). Western blot analysis
using KR127 showed that the preS1(37–119) and
preS1(1–45) retained the binding activity to KR127,
whereas the preS1(38–119) and preS1(1–44) almost
completely lost the binding activity (Fig. 3B). These
data indicate that the epitope of KR127 is located at aa
37–45 of the preS1. The results of the epitope mapping
are summarized in Fig. 1.
Virus-neutralizing activities of KR127 and KR359
antibodies
In vitro neutralization assay (Ryu et al., 1997) was
FIG. 2. Mapping of the epitope recognized by anti-preS1 monoclonal
protein containing a series of deletion mutants as well as molecular we
using KR359 (C, D). The smaller fragments below the main GST-preS1
proteins.employed to assess the virus-neutralizing activities of
KR127 and KR359 antibodies. Adult human hepatocyte
aprimary culture was infected with either the adr (Ryu et
al., 1997) or the ayw (Sells et al., 1987) subtype of HBV
articles, with or without preincubation with various con-
entrations of each antibody, and incubated for 17 days
hile the growth medium was changed every 2 days. On
ay 17 postinfection, the HBsAg secretion by the in-
ected cells was measured by radioimmunoassay. As
hown in Table 1, the HBsAg secretion rate decreased
ith the increasing concentration of antibody, and the
ntibodies almost completely blocked the infection by
oth adr and ayw subtypes of HBV at a concentration of
0 mg/ml. The same results were observed from South-
rn blot analysis of the infected cells on Day 17 using the
32P-labeled HBV DNA as a probe (Fig. 4). No covalently
losed circular (CCC) or single-stranded (SS) form of
BV DNA, which are abundant in active viral replication,
as detected from the cells infected with the mixture of
y KR359. The cell extracts of recombinant E. coli harboring GST fusion
rkers were subjected to 12.5% SDS–PAGE (A, B) and Western analysis
roteins are thought to be partially degraded forms of the preS1 fusionantibod
ight ma
fusion pdr (Fig. 4A) or ayw (Fig. 4B) subtype of HBV with 10











12 MAENG ET AL.subtype-specific anti-preS1 monoclonal antibody 5a-19-1
(Budkowska et al., 1995), included as a control, neutral-
zed only the ayw subtype of the virus. However, it
howed more potent neutralizing activities than either
R127 or KR359. The neutralizing activity of KR127 or
FIG. 3. Mapping of the epitope recognized by anti-preS1 monoclonal ant
ontaining a series of deletion mutants as well as molecular weight marke











ontrold 1.0 (3) 1.0 (8) 1
10 1.2 (4) 2.0 (16) 2
1 5.7 (19) 9.2 (72) 16
0.1 21.6 (71) 9.9 (78) 27
0.01 29.0 (95) 12.6 (99) 34
0 30.5 (100) 12.8 (100) 35
a Antibody concentration.
b The P/N ratio of each antibody-treated sample was divided by tha
c Relative P/N ratio.
d Culture supernatant from uninfected hepatocytes.R359 at 10 mg/ml concentration was almost the same
as that of 5a-19-1 at 0.1 mg/ml concentration (Table 1, Fig.
). The lower neutralizing activities of KR127 and KR359
ay be ascribed to their lower affinities for the virus
article compared with that of 5a-19-1.
R127. The cell extracts of recombinant E. coli harboring GST fusion protein
subjected to 12.5% SDS–PAGE (A, B) and Western analysis using KR127









1.0 (7) 1.0 (2) 1.0 (5)
1.3 (10) 34.8 (77) 1.1 (6)
6.6 (48) 33.9 (75) 1.1 (6)
10.6 (78) 43.7 (96) 1.4 (8)
11.5 (84) 46.5 (102) 10.4 (56)
13.7 (100) 45.4 (100) 18.8 (100)
















13NEUTRALIZING EPITOPES ON HEPATITIS B VIRUS PreS1Binding abilities of KR127 and KR359 to HBV
subtypes and variants
HBV variants carrying mutations on the preS region
have been identified from chronic HBV carriers (Gerken
et al., 1991; Takayanagi et al., 1993; Tran et al., 1991;
FIG. 4. Southern blot analysis of in vitro HBV-neutralization assay.
The intracellular HBV DNA was isolated from uninfected (lane N) or the
infected human hepatocytes by adr (A) or ayw (B) subtype of HBV
preincubated with 10 mg/ml (lane 1), 1 mg/ml (lane 2), 0.1 mg/ml (lane 3),
0.01 mg/ml (lane 4), mock (lane 5) of each of the antibodies (5a-19-1,
KR359, KR127), and subjected to Southern blot analysis using 32P-
labeled 3.2-kb HBV DNA as a hybridization probe. Molecular weight
markers are indicated in kilobases on the left. RC and CCC represent
relaxed circular and covalently closed circular forms of HBV genome,
respectively. SS represents single-stranded HBV DNA. In (B), the RC
form of HBV DNA detected in lane 1 seems to be derived from the HBV
particles that tightly bound to the hepatocytes but did not infect the
cells (Gripon et al., 1993).
FIG. 5. Sequence alignment of aa 17–53 of the various subtypes and
ong, 1995). A hyphen indicates an amino acid residue identical to tha
ines on the top of the sequences. The sequences whose subtypes are
ubtypes are not indicated, those starting with number 20 may be ad
mino acid of ad subtype are missing in ay subtype. The number of identica
atabases are written in parentheses after amino acid sequences.Pollicino et al., 1995) and some immune escape mutants
of HBV with various mutations in the S region have been
reported (Carman et al., 1990; Yamamoto et al., 1994;
Kohno et al., 1996). Therefore, sequence variations of the
two neutralizing epitopes among different subtypes and
variants of HBV were investigated. The amino acid se-
quences of aa 17–53 of all the preS1 listed in GenBank
databases were aligned and compared with those of this
study (Fig. 5). The sequence comparison revealed that
two amino acid substitutions at position 19 (from proline
to serine) and position 25 (from phenylalanine to leucine,
named F25L) occurred in the epitope (aa 19–26) of
KR359, while two amino acid substitutions at position 38
(from serine to threonine) and position 39 (from aspara-
gine to histidine, threonine, or alanine) occurred in the
epitope (aa 37–45) of KR127. No correlation, however,
was found between the type of amino acid changes and
HBV subtypes. In the case of changes outside of the
epitopes, glycine to arginine substitution at position 35
was frequently found in the ayw subtype. The most di-
vergent sequence was identified to carry six substitu-
tions at positions 18, 19, 35, 38, 39, and 51 (named AYW).
The amino acid substitutions at position 48 from aspar-
agine to isoleucine (named N48I) or valine was also
identified.
To test the binding abilities of KR359 and KR127 to the
preS1 variants, the sequences of preS1(1–56) carrying
F25L (S81946), N48I (M74498), or AYW (A32622), as pre-
sented in Fig. 5, were synthesized by recombinant PCR
and expressed in E. coli as GST fusion proteins (Fig. 6A).
Western blot analysis of the cell lysates showed that
KR127 (Fig. 6B) and KR359 (Fig. 6C) bound to all the
preS1 variants tested, indicating that the amino acid
substitutions in the epitope of KR359 or KR127 did not
affect the reactivity of the preS1 with the antibody. The
result suggests that the antibodies could bind to all the
ts of HBV preS1. Query is the preS1 sequence of adr subtype (Kim and
ery sequence. The epitopes of KR359 and KR127 are indicated by the
ed in the GenBank databases are noted. Among the sequences whose
e, while those with number 9 may be ay subtype because the first 11varian
t of qu
identifi














































































14 MAENG ET AL.subtypes of HBV. This is in contrast with ad or ayw
subtype-specific monoclonal antibodies (Petit et al.,
1989; Budkowska et al., 1995).
Since the epitope of KR127 shows the sequence vari-
ation at positions 38 and 39, we examined the impor-
tance of the residues in antibody binding. The preS1(1–
56) mutants carrying alanine substitution at Ser38 or
sn39 were produced and performed Western blot anal-
sis. The result showed that the alanine substitutions did
ot affect the reactivity of the preS1with KR127 (data not
hown), indicating that the two residues are not critical in
ntibody binding. This agrees with the result that KR127
eacted with the preS1 of the ayw subtype as well as the
dr subtype (Fig. 6). It is likely that the residues 38 and 39
ay not interact directly with the antibody-combining site
f KR127. The structural study on the interaction of the
ntibody-combining sites with the epitope remains to be
one for precise explanation.
Several anti-preS1 murine monoclonal antibodies that
ecognize epitopes on the aa 20–50 region are known
Petit et al., 1989; Kuroki et al., 1990; Budkowska et al.,
1995; Kuttner et al., 1999). Of these, F35.25 is ad subtype-
pecific antibody and recognizes the amino-terminal part
f aa 32–53 (Petit et al., 1989), while 5a-19-1 is ayw
ubtype-specific and recognizes aa 36–43 (correspond-
ng to ad subtype) (Budkowska et al., 1995). On the other
and, 116-9 antibody binds to both ad and ay subtypes
nd recognizes aa 27–35 (Mimms et al., 1990; Kuroki et
l., 1990), and MA 18/7 antibody recognizes aa 30–35 of
reS1 (Kuttner et al., 1999). The numbering systems in
escribing the epitopes are used for the ad subtype.
one of these antibodies was demonstrated for the vi-
us-neutralizing activity. Comparison of the epitopes of
he antibodies shows that the epitopes (aa 19–26, 37–45)
f our monoclonal antibodies are different from those of
he other antibodies mentioned earlier, suggesting that
R127 and KR359 are new anti-preS1 monoclonal anti-
FIG. 6. Binding abilities of KR127 and KR359 to preS1 variants. Cell
ysates containing GST (lane 1), the GST fusion proteins with preS1(1–
6) of the query sequence (lane 2), N48I (lane 3), AYW (lane 4), F25L
lane 5), or molecular weight standards (lane M) were subjected to
2.5% SDS–PAGE (A) and Western blot analysis using KR127 (B) or
R359 (C).odies.
In conclusion, we identified the fine epitopes of two
t
enti-preS1 monoclonal antibodies, KR359 and KR127, to
e aa 19–26 and aa 37–45, which are different from those
f previously known monoclonal antibodies, and con-
irmed that the antibodies neutralize both adr and ayw
ubtypes of the virus. The antibodies bound to the preS1
f all the HBV variants tested, suggesting that they may
ind to and neutralize all the subtypes of HBV. The
nformation on the neutralizing epitopes will be useful in
accine development. In addition, these neutralizing
onoclonal antibodies will be valuable in investigating
he mechanism of virus neutralization and the develop-
ent of therapeutics for the prevention and therapy of
BV infection and hepatitis.
MATERIALS AND METHODS
xpression of GST-preS1 fusion proteins
Serially truncated preS1 or preS1(aa 1–56) of adr or
yw subtype were individually expressed as a fusion
rotein with GST. The coding sequences of preS1 of adr
ubtype were synthesized by PCR from pGSTpreS1–56 or
GSTpreS1–119 (adr subtype) (Kim and Hong, 1995) us-
ng 59- and 39-primers and subcloned into the BamHI-
coRI sites of pGEX-2T (Pharmacia) to yield expression
lasmids. The preS1(aa 1–45) of ayw subtype was syn-
hesized by PCR from pAYW (kindly provided by Dr. Y. D.
un at Mogam Institute of Biotechnology, Korea) and
ubcloned into pGEX-2T to yield expression plasmid. The
9- or 39-primer contains a BamHI or EcoRI sequence,
espectively. To construct the preS1 variant, the 59- and
9-DNA fragments containing the mutagenic sequence
ere synthesized by PCR from the pGSTpreS1–56 and
ecombined by subsequent recombinant PCR (Lewis and
rowe, 1991). To express the GST-preS1 fusion proteins,
he expression plasmid was introduced into E. coli DH5a
cells and the expression of the fusion protein was in-
duced by 0.4 mM isoprophyl-b-D-thiogalactopyranoside
t 37°C for 4 h. The induced cells were harvested and
he cell lysates were subjected to 12.5% SDS–PAGE and
estern analysis.
estern analysis
After electrophoresis, protein bands were transferred
o nitrocellulose membrane. Each blot was probed with
nti-preS1 monoclonal antibody, developed with goat
nti-mouse IgG alkaline phosphotase conjugate, and
tained with nitroblue tetrazolium (NBT, GibcoBRL) and
-bromo-2-chloro-3-indolyl phosphate (BCIP, GibcoBRL)
s previously reported (Kim and Hong, 1995).
n vitro neutralization assay
Adult human hepatocytes were prepared by enzymatic
issociation of noncancerous liver fragments and cul-ured as described previously (Gripon et al., 1993). All











15NEUTRALIZING EPITOPES ON HEPATITIS B VIRUS PreS1French laws and regulations, and were approved by the
National Ethics Committee.
In vitro HBV infection and neutralization assays were
carried out as described previously (Gripon et al., 1993;
Ryu et al., 1997). Briefly, human hepatocytes were
seeded at a density of 106 cells per well containing 2 ml
of normal growth medium and were infected 3 days later
with the adr (Ryu et al., 1997) or ayw (Sells et al., 1987)
subtype of HBV particles (about 3 3 107 viral genomic
equivalent). For a neutralization assay, the virus particles
were preincubated with various concentrations of anti-
body at room temperature for 1 h and inoculated onto the
cultured hepatocytes. The hepatocytes were covered
with 1 ml of the serum-free culture medium containing
4% PEG. The infected cells were washed with the growth
medium and further incubated for 17 days, with the me-
dium renewed every 2 days. On Day 17 postinfection, the
culture medium was diluted by 10-fold and the HBsAg
concentration of the diluted culture medium was as-
sayed using a radioimmunoassay kit (Abbott Laborato-
ries, Chicago, IL).
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